CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 901,983	$ 892,812
Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)	95,487	128,644
Selling, general and administrative	351,712	297,917
Research and development	222,847	189,410
Intangible asset amortization	155,730	149,786
Acquired in-process research and development	10,000	1,000
Total operating expenses	835,776	766,757
Income from operations	66,207	126,055
Interest expense, net	(66,116)	(74,147)
Foreign exchange gain (loss)	(1,693)	3,193
Income (loss) before income tax expense (benefit) and equity in loss of investees	(1,602)	55,101
Income tax expense (benefit)	11,669	(15,324)
Equity in loss of investees	1,347	1,005
Net income (loss)	$ (14,618)	$ 69,420
Net income (loss) per ordinary share:
Basic (in dollars per share)	$ (0.23)	$ 1.09
Diluted (in dollars per share)	$ (0.23)	$ 1.04
Weighted-average ordinary shares used in per share calculations - basic (in shares)	62,537	63,494
Weighted-average ordinary shares used in per share calculations - diluted (in shares)	62,537	73,771
Product sales, net
Revenues:
Total revenues	$ 842,102	$ 884,219
Royalties and contract revenues
Revenues:
Total revenues	$ 59,881	$ 8,593